Novellus Systems

Flux Power Appoints Kevin Royal as Chief Financial Officer

Retrieved on: 
Monday, February 26, 2024
Other Energy, Technology, Batteries, Manufacturing, Alternative Energy, Energy, Other Manufacturing, CFO, CPA, Certified Public Accountant, Harding University, Risk management, Electronics, Renewable energy, Sale, Zovio, Novellus Systems, System, History, Blue Coat Systems, HR, Maxwell Technologies, Business administration, Bluecoat, Financial management, Management

Flux Power Holdings, Inc. (NASDAQ: FLUX ), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today announced the appointment of Kevin Royal, CPA, a seasoned finance and accounting executive, as Chief Financial Officer of the Company, replacing Chuck Scheiwe as part of a planned transition given the Company’s strong financial performance and inflection point.

Key Points: 
  • Flux Power Holdings, Inc. (NASDAQ: FLUX ), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today announced the appointment of Kevin Royal, CPA, a seasoned finance and accounting executive, as Chief Financial Officer of the Company, replacing Chuck Scheiwe as part of a planned transition given the Company’s strong financial performance and inflection point.
  • Kevin Royal brings over 20 years of experience as a Chief Financial Officer for four publicly traded companies, with oversight of Finance, Accounting, IT, HR, Legal, Investor Relations, and M&A.
  • As Chief Financial Officer of Flux Power, Mr. Royal will provide financial leadership to assist in building on the Company's goal of delivering value to its shareholders by implementing short, medium and long-range financial planning, budget development, risk management, corporate strategic development, system implementation, process improvement, regulatory compliance reporting, financial reporting for management, internal controls and tax advice.
  • “On behalf of our board and management team, I would like to welcome Kevin as our Chief Financial Officer, and we are privileged to have someone of his caliber and financial skill set serve as our CFO,” said Ron Dutt, Flux Power Chief Executive Officer.

Sportradar Announces Nomination of Two New Directors at Upcoming 2023 Annual General Meeting

Retrieved on: 
Monday, April 24, 2023
Interim, IPO, AT, Novellus Systems, Internet of things, Lam Research, Marketing, VR, Federal Open Market Committee, Scient, AT&T Corporation, AI, ESI Group, Salesforce, Piping Technology and Products, Guidewire Software, Nomination, Management, Blockchain, Ripcord, Sportradar

In addition to Ms. Ramanathan and Mr. Kurtz, the candidates for the seats include seven incumbent directors advanced by the board.

Key Points: 
  • In addition to Ms. Ramanathan and Mr. Kurtz, the candidates for the seats include seven incumbent directors advanced by the board.
  • Currently, Ms. Ramanathan is a member of the board of directors of ESI Group, a French publicly traded company providing virtual prototyping software solutions and services.
  • She has also chaired ESI’s Technology and Marketing Committee and since September 2022 she has chaired ESI’s Compensation Committee and the Nomination and Governance Committee.
  • Jeffery Yabuki, Chairman of the Board of Directors, said: “On behalf of the entire board of directors, we thank Chuck Robel for his outstanding service to Sportradar.

Lam Research Announces New Executive Appointments to Extend Innovation Leadership and Position the Company for Long-Term Growth

Retrieved on: 
Tuesday, February 21, 2023
Semiconductor, Security, Agility, Novellus Systems, Acquisition, Transformation, Engineering, CSBG, Marketing, LRCX, Fernandes, Lam Research, Management, Varadarajan, Vahedi, Lam

Effective March 1, 2023, new leadership appointments include Pat Lord moving into the newly created position of executive vice president and chief operating officer (COO).

Key Points: 
  • Effective March 1, 2023, new leadership appointments include Pat Lord moving into the newly created position of executive vice president and chief operating officer (COO).
  • Vahid Vahedi will take on the role of senior vice president and chief technology officer (CTO) – succeeding Rick Gottscho, who begins a new executive leadership position at the company focused on the innovation ecosystem.
  • Lord, Vahedi, Gottscho, Varadarajan and Fernandes will report directly to Tim Archer, president and chief executive officer at Lam.
  • "Pat, Vahid, Rick, Sesha and Neil exemplify the Lam core values of agility, achievement, and innovation and continuous improvement.

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Growth, Annual report, University, International, MD, Securities Exchange Act of 1934, Acquisition, Method, Immunity, Tissue, Hashimoto, MD Anderson Cancer Center, Cancer, GLOBE, Research, Palestinian National Interest Committee, U.S. Securities and Exchange Commission, Nasdaq, COVID-19, Novellus Systems, Securities Act of 1933, Cell, Terminology, Interim, Technology, AML, Cell engineering, Private Securities Litigation Reform Act, Company, Gene editing, IPS, Communication, Acute myeloid leukemia, Patient, Sumathi Best Television Current Reporting Award, SAN, Forward-looking statement, ERNA, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Vaccine, Leukemia, Eterna

We are excited to announce this research agreement to advance a central pillar of Eternas pipeline: allogeneic cell therapies for the treatment of cancer, said Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna.

Key Points: 
  • We are excited to announce this research agreement to advance a central pillar of Eternas pipeline: allogeneic cell therapies for the treatment of cancer, said Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna.
  • at the International Societyfor Cell & Gene Therapy 2021 Annual Meeting, and Eterna believes the advantages of its cells include exceptional manufacturing consistency due to the use of a highly characterized clonal iPS cell source.
  • Eternas completely non-viral approach to cell engineering avoids the risks inherent in other methods, said Roger Sidhu, M.D., Chief Medical Officer of Eterna.
  • Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology.

University of Arkansas Contracts Dalrada Corporation’s Deposition Technology Ltd. to Build a Plasma Enhanced Chemical Vapor Deposition Tool

Retrieved on: 
Monday, October 31, 2022
Technology, Research, Semiconductor, Engineering, Chemicals, Plastics, Manufacturing, University, Science, Education, EVOS, OEM, PVD, University, Music, Semiconductor, Annual report, Research, Industry, Novellus Systems, U.S. Securities and Exchange Commission, Spacecraft Fabrication Facility (Goddard), Silicon, View, State Institute for Music Research, Behavior, Technology, Company, Form 10-K, Silicon carbide, Solution, OTCQB, 3D printing, Ceramic, Facebook

A primary mission of the facility is to bridge the gap between basic research and high-volume manufacturing by offering industry-compatible prototyping fabrication.

Key Points: 
  • A primary mission of the facility is to bridge the gap between basic research and high-volume manufacturing by offering industry-compatible prototyping fabrication.
  • Dalrada continuously creates innovative, impactful solutions to address the complex challenges of today and the future.
  • Dalrada Financial Corporation is committed to positively impacting people, businesses, and the planet through sustainable solutions.
  • The University of Arkansas Multi-User Silicon Carbide Fabrication and Research Facility will be the only openly accessible fabrication facility in the U.S.

Velo3D Appoints Jessie Lockhart as Chief People Officer

Retrieved on: 
Thursday, October 20, 2022
Other Manufacturing, Technology, Engineering, Chemicals, Plastics, Other Technology, Automotive Manufacturing, Aerospace, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, People, Adoption, LinkedIn, Education, Bay, Master of Business Administration, Culture, SEC, Growth, Business administration, AM, All rights reserved, Employment, NYSE, Psychology, FLOW, Novellus Systems, Twitter, Workforce, Multimedia, Defence Intelligence Fusion Centre, Technology, Private Securities Litigation Reform Act, Pepperdine University, CPP, Company, Acquisition, San Francisco, SpaceX, Flow, CEO, Lam Research, Optimism, Leadership, Bachelor, Quality assurance, Honeywell, Aviation, Solution, SAPPHIRE, View, San Jose State University, VELO, VLD, Management, 3D printing, Risk management, Sapphire

Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Jessie Lockhart as Chief People Officer.

Key Points: 
  • Velo3D , Inc. ( NYSE: VLD ), a leading metal additive manufacturing technology company for mission-critical parts, today announced it has appointed Jessie Lockhart as Chief People Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221020005413/en/
    Jessie Lockhart, Chief People Officer at Velo3D (Photo: Business Wire)
    Velo3D has experienced extensive growth in its workforce over the past year since becoming a publicly listed company, including rapid expansion in Europe and Asia-Pacific.
  • Jessie brings with her an amazing background of working with high-growth, innovative companies that have successfully undergone periods of rapid expansion.
  • VELO, VELO3D, SAPPHIRE, and INTELLIGENT FUSION, are registered trademarks of Velo3D, Inc.; and WITHOUT COMPROMISE, FLOW and ASSURE are trademarks of Velo3D, Inc. All Rights Reserved Velo3D, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005413/en/

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

Retrieved on: 
Thursday, September 1, 2022
Security (finance), COVID-19, Onyx Pharmaceuticals, Strategic planning, Research, Myers, PricewaterhouseCoopers, McKinsey & Company, Forward-looking statement, Wilson Sonsini Goodrich & Rosati, U.S. Securities and Exchange Commission, Yahoo!, GLOBE, Assertio Therapeutics, Leadership, Nasdaq, Privacy, Compliance, Revolution, Biotechnology, SHP2, RAS, Terminology, Intellectual property, Amgen, Novellus Systems, Private Securities Litigation Reform Act, Ras GTPase, Helmy Eltoukhy, Drug development, Acquisition, Contract, Management, Pharmaceutical industry

REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced two senior management promotions, as well as the addition of a new member to its leadership team. Jack Anders, who previously served as the company’s senior vice president, finance and principal financial and accounting officer, has been promoted to chief financial officer, and Jeff Cislini, formerly vice president, deputy general counsel, has been promoted to senior vice president, general counsel and corporate secretary. Additionally, Daniel Simon will join the company as chief business officer in early September.

Key Points: 
  • He joined Revolution Medicines in 2020 as its deputy general counsel and has served as the companys senior legal advisor during his tenure.
  • Mr. Simon joins Revolution Medicines from Guardant Health where he most recently served as the companys senior vice president, biopharma business development.
  • The promotions of Jack and Jeff are well-deserved and speak to the important contributions that they have each made to the success of Revolution Medicines as members of the management team.
  • We are also excited to welcome Daniel to the Revolution Medicines team as the companys first chief business officer.

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022
COVID-19, U.S. Securities and Exchange Commission, Risk, Company, Consultant, Immunotherapy, G&A, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Food, Pivotal, Peripheral T-cell lymphoma, T-cell lymphoma, Potency (pharmacology), Patient, Insurance, Quality of life, CGMP, BLA, PTCL, Research, Patent, FDA, Securities Act of 1933, Accounting, Securities Exchange Act of 1934, Hemorrhoid, CRO, Forward-looking statement, IL-2R, Drug Quality and Security Act, Calendar, Regulation, Fast Track, SEC, Annual report, CTCL, CEO, Pharmaceutical industry, Security (finance), Fine chemical, Online gambling, Airline, Citius, Altius, Fortius, Novellus Systems

CRANFORD, N.J., May 12, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today reported business and financial results for the second fiscal quarter of 2022 ended March 31, 2022.

Key Points: 
  • "The Citius balance sheet remains healthy with $55.8 million in cash available to execute our near-term plans.
  • As stewards of Citius shareholders' capital, we focus on creating long-term value in the business and will continue to evaluate all strategic and financial options available to us.
  • SECOND QUARTER ENDED MARCH 31, 2022 Financial Results:
    As of March 31, 2022, the Company had $55.8 million in cash and cash equivalents and no debt.
  • For the fiscal quarter ended March 31, 2022, stock-based compensation expense was $1.0 million as compared to $0.3 million for the prior year period.

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Friday, April 15, 2022
Head, NTN Buzztime, COVID-19, Research, U.S. Securities and Exchange Commission, Annual report, Degenerative disease, Science, Private Securities Litigation Reform Act, NYSE American, GLOBE, Sale, Terminology, Securities Act of 1933, NBI, Patient, Gene editing, SAN, Securities Exchange Act of 1934, Growth, Technology, Insurance, Company, Communication, NASDAQ Biotechnology Index, Forward-looking statement, NYSE, Safety, Monogenic, Industry, RNA transfection, Acquisition, NTN, Cancer, Survival, Pharmaceutical industry, Animal, Management, Vaccine, Cryptocurrency, Novellus Systems, Nasdaq

(Nasdaq:BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • (Nasdaq:BTX) (Brooklyn), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021.
  • Our accomplishments in 2021 reflect our continued progress towards our vision of transforming patients lives through science.
  • As of December 31, 2021, Brooklyn had approximately $17.0 million in cash, compared to $1.6 million as of December 31, 2020.
  • Securities and Exchange Commission, particularly under the heading Risk Factors in Brooklyns Annual Report on Form 10-K for the year ended December 31, 2021.

Dalrada Corporation Expands Technology Division With Acquisition of Deposition Technology Ltd.

Retrieved on: 
Thursday, April 7, 2022
Data Management, Technology, Semiconductor, Security, Networks, Alternative Energy, Internet, Energy, Mobile, Wireless, Hardware, Electronic Design Automation, EVOS, Company, Perseverance, Plasma, Growth, Novellus Systems, Annual report, ESG, SEC, Corporation, CEO, Form 10-K, Carbon, OEM, Sustainable energy, View, Industry, Technology, Acquisition, Goal, PVD, U.S. Securities and Exchange Commission, MEMS, OTCQB, Solution, Mackenzie, Renewable energy

Dalrada Corporation (OTCQB: DFCO , Dalrada) is pleased to announce the acquisition of Deposition Technology Ltd. (DepTec) as the company continues its growth within the global technology and clean energy sectors.

Key Points: 
  • Dalrada Corporation (OTCQB: DFCO , Dalrada) is pleased to announce the acquisition of Deposition Technology Ltd. (DepTec) as the company continues its growth within the global technology and clean energy sectors.
  • The acquisition allows both teams to expand capacity and improve design and support for Dalradas range of field-based equipment.
  • For semiconductor, micro-electromechanical systems (MEMS), and medical and optoelectronics device manufacturers, DepTec manufactures chemical vapor and physical vapor deposition systems.
  • Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies.